Tesamorelin: What Four Pooled Trials in 909 Patients Found

A meta-analysis published July 31, 2026 in the Journal of the International Association of Providers of AIDS Care pooled all four randomized controlled trials of tesamorelin ever run, 909 patients in total. Compared with placebo, visceral fat fell 21.5 cm2, trunk fat fell 1.2 kg, waist circumference fell 1.6 cm, and lean body mass rose 1.4 kg.

That is the entire randomized record for tesamorelin, a growth hormone releasing hormone (GHRH) analog, now sitting in one place with pooled effect sizes attached. If you have wondered what a "GH peptide" does to body composition in a controlled trial rather than in a sales page, this is the closest thing to an answer. The answer is narrower than the marketing, and it comes with a very specific population attached.

What a GHRH analog actually does

Your pituitary releases growth hormone in pulses, mostly overnight. According to the FDA prescribing information for EGRIFTA WR, current as of its 2025 revision on DailyMed, tesamorelin is a growth hormone releasing factor analog that binds GRF receptors on the pituitary and stimulates the synthesis and pulsatile release of your own growth hormone. Growth hormone is both lipolytic (it mobilizes fat) and anabolic (it builds lean tissue). Tesamorelin is one of several GHRH analogs built around that same signal; sermorelin works through the same receptor pathway, though the published research behind it covers a different population entirely.

The mechanistic difference from injected growth hormone is that tesamorelin acts upstream. It prompts the pituitary rather than replacing its output, so release stays pulsatile and stays subject to the body's own feedback loops. That is the theory. What the trials measured is whether it changes anything you can scan.

What changed across the pooled trials

The four pooled trials, all of them funded by the drug's manufacturer, Theratechnologies, compared 2 mg of tesamorelin daily against placebo over durations ranging from 12 to 52 weeks. Across 909 participants, the differences versus placebo were:

• Visceral adipose tissue: down 21.47 cm2 (95% CI -34.73 to -8.22, p=0.002)
• Trunk fat: down 1.20 kg (95% CI -1.47 to -0.93, p<0.00001)
• Waist circumference: down 1.61 cm (95% CI -2.28 to -0.95, p<0.00001)
• Lean body mass: up 1.42 kg (95% CI 1.13 to 1.71, p<0.00001)
• IGF-1: up 109.10 ng/mL (p<0.000001)

These are averages observed in those trial participants, not a forecast of what any individual would get.

Duration was the whole story for visceral fat

The headline visceral fat number hides a split worth understanding. In trials running 26 weeks or longer, visceral adipose tissue fell 27.15 cm2 (95% CI -38.08 to -16.22, p<0.00001), and the trials agreed closely with each other. In trials shorter than 26 weeks, the pooled difference was 0.10 cm2 (95% CI -18.44 to 18.64, p=0.99). Nothing. The overall estimate carried substantial statistical heterogeneity, and that duration split accounts for most of it.

The pivotal trial points the same way. In the 412-patient randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2007 - which, like all four pooled trials, was funded and designed by the manufacturer, Theratechnologies - 26 weeks of daily 2 mg tesamorelin decreased CT-measured visceral fat by 15.2% while placebo rose 5.0% (p<0.001). The meta-analysis that pooled these trials was itself independent: its authors reported no financial support and no conflicts of interest.

What did not change

This half is as informative as the first.

Triglycerides did not budge in the pooled analysis: 0.02 mmol/L, p=0.94, with high heterogeneity between trials. The 2007 NEJM trial had found triglycerides falling 50 mg/dL against a 9 mg/dL rise on placebo (p<0.001), but that result did not survive pooling with the other three trials. Total cholesterol moved slightly, down 0.16 mmol/L (p=0.003), roughly 6 mg/dL.

Glycemic measures were flat. Fasting glucose differed by 1.51 mg/dL (p=0.17), two-hour glucose by 1.20 mg/dL (p=0.84), fasting insulin by -0.72 microunits/mL (p=0.66). None statistically significant.

Weight was not a target. The FDA prescribing information for EGRIFTA WR states the product is not indicated for weight loss management and describes a weight-neutral effect. Fat came off the trunk, lean mass went up, and the scale stayed put.

Who these 909 patients were

Every one of the four pooled trials studied people living with HIV who had developed lipodystrophy on antiretroviral therapy, meaning a specific pattern of excess visceral abdominal fat. Mean age was 48.5 years, 83.4% were male, mean BMI was 29.1 and mean waist circumference was 104.79 cm, and participants were predominantly White.

The FDA-approved indication matches that population exactly. Per the prescribing information, "EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy."

There is no pooled randomized evidence here for anyone else. Not for healthy adults seeking body recomposition, not for age-related visceral fat, not for postmenopausal women. The meta-analysis authors specifically flag the more than 85% male sample as a limit on generalizing to women. Applying these numbers outside that population is an extrapolation, not a finding.

Risks, unknowns, and what this tells you

In the pooled trials, discontinuation due to adverse events carried a risk ratio of 2.25 (95% CI 0.98 to 5.17, p=0.06). That did not reach statistical significance and the interval crosses 1, but the point estimate is more than double and worth knowing. Serious adverse events were comparable (RR 1.07, p=0.85). Paresthesia, myalgia and limb pain were all numerically more common on tesamorelin without reaching significance.

The label adds more. FDA prescribing information for EGRIFTA WR warns on neoplasms, with active malignancy listed as a contraindication; glucose intolerance, where 5% of recipients reached an HbA1c of 6.5% or higher versus 1% on placebo; fluid retention including edema, arthralgia and carpal tunnel syndrome; and injection site reactions in 25% versus 14%. It also states that long-term cardiovascular safety has not been established. Note the tension: pooled trial glucose measures were flat, while the label reports an HbA1c signal. Both are accurate, and they are measuring different things over different windows.

The meta-analysis authors list their own limits plainly: only four trials, only one dose studied, follow-up capped at 52 weeks and therefore too short to speak to long-term safety, inconsistent patient-reported outcomes, and a mostly male sample.

So the honest summary is this. In people living with HIV and lipodystrophy, taking at least six months, tesamorelin produced a moderate reduction in visceral fat and a small gain in lean body mass, without changing weight, triglycerides or glucose. Outside that population, nobody has run the trial. And a compounded peptide sold as tesamorelin is not the FDA-approved product and has not been evaluated by the FDA for safety or effectiveness. If you are weighing any of this, that conversation belongs with a licensed provider who can look at your actual markers.